Apr 11, 2023 8:10am EDT Ensysce Biosciences Announces Updated Investor Presentation Available Via Investor Relations Website
Apr 03, 2023 8:00am EDT Ensysce Biosciences Announces Positive Results from Oral Human Abuse Potential Trial for PF614
Mar 30, 2023 5:37pm EDT Ensysce Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results
Mar 22, 2023 8:05am EDT Ensysce Biosciences Announces Completion of Enrollment for Groundbreaking Opioid Overdose Protection Study
Mar 06, 2023 8:05am EST Dr. Lynn Kirkpatrick, Featured Speaker to Discuss Ensysce Overdose Protection Platform at DCAT Seminar
Feb 28, 2023 8:05am EST Ensysce Biosciences Announces Critical Step in Human Abuse Potential Study of PF614 With Database Lock
Feb 14, 2023 8:00am EST Ensysce Biosciences to Present its Overdose Protection Program at the 4th Annual NIH 'HELPING END ADDICTION LONG-TERM' (HEAL) Meeting
Feb 07, 2023 8:05am EST Ensysce Biosciences, Inc. Announces Closing of $3.0 Million Registered Direct Offering Priced at-the-Market Under NASDAQ Rules